Emerging Markets Sebia has scored recognition as a Top Emerging MedTech Company in India and has ongoing collaboration with Indian diagnostics players, indicating strong growth potential in the India market. Sales opportunities include expanding lab partnerships, distribution agreements, and co-developed offerings for autoimmune, infectious disease, and multiple myeloma testing in this region.

Product Expansion The company is expanding its US portfolio and enhancing workflow integration for hemoglobinopathy testing, with solutions that reduce manual intervention and improve traceability. Potential upsell opportunities exist for full automation and data management integration across CAPILLARYS 3 systems and ELISA/IFA platforms to modernize existing labs.

Strategic Collaborations Sebia has engaged in partnerships and potential deals for multiple myeloma diagnostics, including collaborations with Janssen Biotech and other labs. This presents openings for co-marketing, bundled instrument and reagent offerings, and service-level agreements targeting high-throughput oncology diagnostics.

MRD and M-profiling Recent launches in minimal residual disease testing and serum-based disease monitoring position Sebia to offer integrated MRD workflow components, including assays, automated imaging, and data interpretation. Opportunities exist to position end-to-end MRD solutions to hematology-oncology labs seeking standardized monitoring.

Instrumentation & Automation Sebia’s CAPILLARYS 3 multi-assay systems and fully automated IFA/ELISA platforms enable high-throughput, walkaway operation. The sales angle includes targeting mid-to-large-sized labs needing scalable, traceable, and compliant workflows, plus integration with ERP and IT stacks such as SAP and OneTrust for enterprise deployments.